Month: June 2026

Introduction and Objective: GLP-1 receptor agonists (GLP-1RAs) effectively treat type 2 diabetes and obesity but frequent injections may limit adherence. PT403 is a long-acting semaglutide formulation based on biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres designed for once-monthly administration. This study evaluated the pharmacological efficacy, safety, and tolerability of PT403 and explored its translational development potential as […]

Introduction and Objective: Lean mass loss during pharmacologic weight reduction remains a key limitation of current obesity therapies. BG-104 is a multi-pathway therapeutic integrating GLP-1, GIP, and human growth hormone (hGH) receptor agonism with Activin Type II Receptor (ActRII) targeting to promote adiposity reduction while preserving skeletal muscle.Methods: Metabolic and body composition effects were evaluated […]

Introduction and Objective: Given the global diabetes epidemic, the burden of inpatient glycemic care continues to increase. Poor inpatient glycemic control is associated with adverse patient outcomes, yet scalable hospital-wide solutions for real-time glucose management remain limited. We evaluated the long-term impact of an electronic medical record (EMR)-integrated, hospital-wide remote glycemic management system at a […]

Introduction and Objective: Incretin-based therapies have emerged as effective interventions for weight management. While small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as Orforglipron, demonstrate meaningful clinical efficacy, evidence from MariTide indicates that simultaneously agonizing GLP-1R and antagonizing glucose-dependent insulinotropic polypeptide receptor (GIPR) pathways can provide more robust outcomes than targeting GLP-1R alone. Here we report […]

Introduction and Objective: CGM is increasingly used among adults with T2D, including non-insulin-treated patients in primary care. It may enable more timely assessment and care quality control during ongoing digital health interventions. This study evaluated weekly changes in CGM-derived glycemic metrics and compared HbA1c outcomes with BGM users in a digital health program.Methods: Data from […]

Introduction and Objective: GZR102 injection (GZR102) is a novel once-weekly fixed-ratio combination (FRC) of insulin GZR4 and the GLP-1 analog bofanglutide (GZR18). GZR102 is designed to preserve the pharmacokinetic (PK) characteristics of the individual components while delivering complementary glycemic control and metabolic benefits in people with T2DM.Methods: Potential drug-drug interactions (DDI) were assessed. PK profiles […]

Introduction and Objective: Type 2 diabetes frequently presents with comorbidities including hypertension, obesity, hypertriglyceridemia, thyroid disorders, myocardial infarction, and chronic kidney disease. Hypertriglyceridemia is linked to insulin resistance and elevated blood glucose. This study evaluated the safety and efficacy of saroglitazar, a dual PPAR-α/γ agonist, in Indian adults with type 2 diabetes and comorbidities.Methods: This […]

Introduction and Objective: TLC-1180 (1180) is a liver-targeted mitochondrial protonophore in clinical development. Insulin resistance is a major factor in the pathogenesis of T2D and metabolic alterations associated with insulin resistance are linked to heart failure with preserved ejection fraction (HFpEF). This study aims to evaluate the effects of 1180 on tissue specific insulin resistance […]

Introduction and Objective: This study investigated the glucodynamics and hypoglycemia risk associated with exercise or fasting during once-weekly basal insulin icodec treatment.Methods: Thirty basal insulin-treated, physically active individuals with T2D were enrolled. Icodec was dosed for ≥7 wks to target FPG of 80-130 mg/dL. When icodec steady state was achieved, 40 min cycling (EXE; 60% […]